|
Federal
Register Notices > Manufacturers 2008
>
Alltech Associates Inc.
FR Doc E8-6359[Federal Register: March 28, 2008 (Volume 73, Number 61)]
[Notices] [Page 16719] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28mr08-122]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec.
1301.33(a), Title 21 of the Code of Federal Regulations (CFR),
this is notice that on February 29, 2008, Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made application to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the basic
classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
N,N-Dimethylamphetamine (1480)
|
I
|
|
4-Methylaminorex (cis isomer) (1590)
|
I
|
|
Alpha-ethyltryptamine (7249)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
2,5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Alpha-methyltryptamine (7432)
|
I
|
|
Bufotenine (7433)
|
I
|
|
Diethyltryptamine (7434)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
5-Methoxy-N,N-diisopropyltryptamine (7439)
|
I
|
|
N-Ethyl-1-phenylcyclohexylamine (7455)
|
I
|
|
1-(1-Phenylcyclohexyl) pyrrolidine (7458)
|
I
|
|
1-Phenylcyclohexylamine (7460)
|
I
|
|
1-[1-(2-Thienyl) cyclohexy] piperidine (7470)
|
I
|
|
Normorphine (9313)
|
I
|
|
Methamphetamine (1105)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Phenylacetone (8501)
|
II
|
|
1-Piperidinocyclohexanecarbonitrile (8603)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Dihydromorphine (9145)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Meperidine intermediate-B (9233)
|
II
|
|
Noroxymorphone (9668)
|
II
|
The company plans to manufacture high purity drug standards used for
analytical application only in clinical, toxicological, and forensic
laboratories.
Any other such applicant and any person who is presently registered with DEA
to manufacture such substance may file comments or objections to the issuance of
the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or
objections being sent via regular mail should be addressed, in quintuplicate, to
the Drug Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), Washington, DC 20537; or any being sent via
express mail should be sent to Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and must be filed no later than May 27,
2008.
Dated: March 19, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-6359 Filed 3-27-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
